Clinical trial
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial…
NCT00477594 · Kastle Therapeutics, LLC, Industry · Completed
Key facts
| NCT number | NCT00477594 |
|---|---|
| Title | Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia |
| Official title | An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia |
| Lead sponsor | Kastle Therapeutics, LLC, Industry |
| Collaborators | Ionis Pharmaceuticals, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Genetic Diseases, Inborn and 8 more |
| Intervention type | Drug |
| Interventions | mipomersen sodium |
| Enrollment | 21 |
| Start date | May 1, 2007 |
| Primary completion | Mar 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | May 24, 2007 |
| Last update posted | Sep 9, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: